INTRODUCTION
Type 2 diabetes mellitus (T2DM), a metabolic disorder, is a major global health-care problem. [1, 2] The World Health Organization has predicted that the global prevalence of diabetes will increase from 2.8% in 2000 to 4.4% in 2030. [1] A main function of Vitamin D is to regulate calcium and phosphorus homeostasis and bone metabolism. [3] Vitamin D may influence several nonskeletal medical conditions, including cardiovascular disease, cancer, autoimmune disorders, psoriasis, multiple sclerosis, and T2DM. [4] [5] [6] It has been reported that there is an inverse relationship between circulating levels of Vitamin D and the prevalence of T2DM. In fact, Vitamin D deficiency has being suggested as a risk factor for T2DM. [7, 8] Some studies have shown are antioxidant enzymes that protect the body against active oxygen-free radicals. [14, 15] Some experimental studies showed that Vitamin D may have antioxidant properties by modifying some of the antioxidant enzymes. [16, 17] Therefore, the aim of this study was to investigate the levels of 25-hydroxy Vitamin D (25[OH] D) in patients with T2DM and in nondiabetic healthy controls and to ascertain the impact of 25(OH)D levels on glycemic control and oxidative stress in T2DM patients.
MATERIALS AND METHODS
This is a case-control study including thirty cases. Inclusion criteria were all cases diagnosed as male patients with T2DM, aged 36-53 years, attending the outpatient clinics of Kasr El Ainy Hospital, Cairo University. Twenty healthy males of comparable age and socioeconomic status served as a control group. The study was conducted in October 2014. Exclusion criteria included use of drugs which affect calcium and bone metabolism, chronic disorders of liver and kidney, cancer, endocrinology disorders such as hypo-or hyper-thyroidism and hyperparathyroidism, insulin injection, use of anticonvulsion drugs, Vitamin D, and calcium supplementation. A written informed consent of participation in the study was taken from all participants. This study was approved by the Committee of Ethics and Research of the university hospital. Weight and height were measured, and the body mass index (BMI) was calculated by dividing body weight by squared height (kg/m 2 ). Venous blood samples were drawn in a fasting state from all the participants. Blood samples were left to clot at room temperature and centrifuged, and the serum was separated and stored at −20°C until further analysis.
• Serum glucose concentrations (fasting blood sugar [FBS] and postprandial blood sugar [PP]) were measured by glucose oxidase method (Beckman Glucose Analyzer, Fullerton, CA, USA) • HbA1c for patients was measured by affinity chromatography test using Biosystem kit, USA • Serum levels of 25(OH)D were determined using radioimmunoassay (RIA) technique by using 25(OH)D 125 I RIA kit (DiaSorin, USA) • SOD activity was determined using the method of Sun et al. [18] GPx activity was measured by the method of Paglia and Valentine. [19] 
Statistical analysis
The results were expressed as mean ± standard error. The statistical difference between groups was analyzed using Student's t-test. Pearson's correlation analysis was performed to determine the relationships between variables. The results were considered significant at P < 0.05. The statistical calculations were done using Statistical Package for the Social Sciences version 15 software, while the presentations were performed using Microsoft Excel 2007.
RESULTS
Serum Vitamin D levels were significantly lower in patients with T2DM than healthy controls (P = 0.015) [ Figure 1 ]. Patients with T2DM had higher BMI as well as FBS and PP than healthy controls (P = 0.012, P = 0.000, and P = 0.000, respectively) [ Table 1 ]. There was a significantly lower GPx activity in patients with T2DM as compared with those of healthy controls (P = 0.048), but the difference in SOD activity did not reach statistical significance [ Table 1 ]. Table 2 illustrates the correlation between different studied parameters in patients with T2DM. There was a significant negative correlation between serum Vitamin D levels and HbA1c (P = 0.016), and also there was a negative correlation between serum Vitamin D levels and PP (P = 0.018), but no statistical correlation was shown between serum Vitamin D levels and FBS, GPx, and SOD. In addition, GPx and SOD had no statistical correlation with HbA1c.
DISCUSSION
T2DM is a progressive disease characterized by insulin resistance and β-cell dysfunction that ultimately leads to altered insulin secretion. [9] The pathogenesis of T2DM is multifactorial. Environmental factors play an important role either as triggers or even have protective role. [9, 20] One among the environmental factors which may play a role in T2DM pathogenesis is Vitamin D deficiency. [21] Vitamin D plays a wide range of functions in our body such as regulation of mineral homeostasis, bone remodeling, and also plays a role in immune system. [22] Apart from these well-known functions, many studies have shown that Vitamin D also plays an important role in β-cell function, insulin sensitivity, and secretion by both direct and indirect actions. [22] In our study, we found that serum 25(OH)D levels were significantly lower in the group of T2DM patients compared to control group. Similar results are reported in previous studies.
[ [23] [24] [25] Need et al. [26] showed that the patients who had higher levels of Vitamin D concentration had lower FBS in comparison with the other groups. In contrast, other studies, have not shown any difference in 25(OH)D between patients with diabetes compared to normal population. [27, 28] In T2DM, the role of Vitamin D was suggested from the presence of Vitamin D receptors (VDR) on the pancreatic β-islet cells. In these cells, the biologically active metabolite of Vitamin D (i.e., 1,25-dihydroxy Vitamin D[1,25(OH) 2 D]) enhances insulin production and secretion via its action on the VDR. [29] Several studies demonstrated a relationship between single-nucleotide polymorphisms in the genes regulating VDR and Vitamin D binding protein and glucose intolerance and insulin secretion. [30] [31] [32] This further supports a role for Vitamin D in T2DM and may explain the reduced overall risk of the disease in subjects who ingest >800 IU/day of Vitamin D. [33] However, an alternative, perhaps related, explanation was proposed for the role of Vitamin D in the prevention of T2DM based on its potent immunomodulatory functions. [34] 1,25(OH) 2 D modulates the production of the immunostimulatory interleukin (IL)-12 and the immunosuppressive IL-10, [35] and VDRs are present in most types of immune cells. [36] Vitamin D protect β-cells against cytokine-induced apoptosis. [37] In our study, Vitamin D levels were found to be negatively correlated with HbA1c levels. This was in agreement with other studies. [38, 39] HbA1c is considered an indicator of average blood glucose concentrations during the preceding 2-3 months and thus a long-term marker of glucose homeostasis. [40] There was a negative correlation between Vitamin D levels and PP, but no correlation between fasting glycemia and 25(OH)D was found, although that, Vitamin D levels being related to glycemic control where HbA1c reflects glucose control over time and it is more accurate than FBS and PP.
We found a nonsignificant difference in SOD activity in patients with T2DM when compared to controls. SOD is considered to be the first line of defense against oxidation stress; it protects the body against active oxygen-free radicals by scavenging excess superoxide to form hydrogen peroxide which is then converted to water by GPx enzyme. [41] Our results revealed that GPx activity was significantly low in patients with T2DM, indicating decreased scavenging capacity of glutathione-dependent antioxidant defense system against elevated lipid peroxidation processes in these patients. There was no significant correlation between serum levels of 25(OH)D and activities of GPx and SOD enzymes in patients with T2DM in our study.
There is contradiction about the activity of antioxidant enzymes in diabetes mellitus. Both increased and decreased activities of these enzymes were reported in experimental and trial studies. [42] Saedisomeolia et al. [43] showed lower activity of SOD and higher activities of GPx and glutathione reductase (GR) in patients with T2DM compared to controls. The main new finding of their study was determining the association between serum levels of 25(OH)D and activity of antioxidant enzymes in patients with T2DM and healthy controls. Results of their study indicated an inverse relationship between serum levels of 25(OH)D and activities of GPx and GR and a positive trend with SOD in patients with diabetes. Hisalkar et al. [44] revealed a significant fall in both SOD and GPx activities in patients with T2DM when compared to controls which was in agreement with our results regarding GPx activity. Similar findings were reported by various authors. [45, 46] It was suggested that in the early stage of T2DM, the antioxidant defense system counters the effects of increased free radicals, so it was supposed that the antioxidant enzymes activities increased as a compensatory response to oxidative stress, but by the advanced stage, the balance between generation of free radicals and antioxidant defense is impaired as a result of decreased antioxidant activities due to their possible depletion. [47] There is a considerable body of evidence indicating that hyperglycemia may interfere with natural defense of the antioxidant system, in addition to increasing the production of free radicals. [48] Since SOD enzyme is part of the first line of defense against free radicals, it is expected that the activity of this enzyme may be affected by oxidative stress before the other antioxidant enzymes. [49] Taheri et al. [47] indicated that SOD activity was lower in patients with diabetes compared with healthy controls. There is evidence to show that hyperglycemia is accompanied by the loss of Cu 2+ , which is an essential cofactor in SOD activity, and SOD is inactivated by glycosylation in erythrocytes. [49] As hyperglycemia, a hallmark of diabetic condition, depletes natural antioxidants and facilitates the production of reactive oxygen species (ROS) through glucose autoxidation and nonenzymatic glycation of proteins, [50] and as Vitamin D levels were related to glycemic control in patients with T2DM as indicated in our study, Vitamin D supplementation can improve oxidative stress in patients with diabetes by improving glucose control. Several studies on experimental models showed that Vitamin D has antioxidant properties. [16, 17, 49, 51] Wiseman [52] reported that Vitamin D3 can inhibit lipid peroxidation induced by iron in brain liposome; therefore, Vitamin D could serve as cellular membrane antioxidant. Anticancer activity of Vitamin D is also attributable to its antioxidant property. [53] Mukhopadhyay et al. [17] also conducted a study in murine lymphoma and concluded that the anticancer effect of Vitamin D3 is mainly through its antioxidant potential. Vitamin D can be considered as a casual antioxidant which scavenges ROS in the first stage before activation of other stress-sensitive response pathways; on the other hand, Vitamin E or other antioxidants may be considered a more "symptomatic" rather than a causal treatment for oxidative stress because these antioxidants scavenge the already formed oxidants. [54] This study showed that Vitamin D levels appear to be lower in patients with T2DM than in the control group and Vitamin D levels were related to glycemic control in T2DM. The study had some limitations; the sample size was small and the sunlight exposure of each individual varies on a daily basis.
CONCLUSION
Low level of Vitamin D might play a significant role in T2DM pathogenesis and this finding may have therapeutic implications as cautious Vitamin D supplementation may improve glycemic control and oxidative stress in T2DM.
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